Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays

Journal of Drug Targeting

Volumn 14, Issue 9, 2006, Pages 614-622

  Sanchez De Juan, Berta ^a   Von Briesen, Hagen ^b   Gelperina, Svetlana E ^c   Kreuter, Jög ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR BIOMEDICAL ENGINEERING   (Germany)

^c Research Center of Molecular Diagnostics and Therapy   (Russian Federation)

Author keywords

Cytotoxicity; Doxorubicin; Poly (butyl cyanoacrylate) nanoparticles; Rat glioma cell lines; Surfactants

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYANOACRYLATE DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; LACTATE DEHYDROGENASE; MANNITOL; POLOXAMER; POLOXAMINE 908; POLY(BUTYLCYANOACRYLATE); POLYSORBATE 80; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG RESPONSE; GLIOMA; GLIOSARCOMA; NANOPARTICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SOLUTION AND SOLUBILITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GAS; DOXORUBICIN; ENBUCRILATE; EXCIPIENTS; FLOW CYTOMETRY; GLIOMA; L-LACTATE DEHYDROGENASE; MICROSCOPY, CONFOCAL; NANOPARTICLES; P-GLYCOPROTEIN; RATS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33750827843     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600866872     Document Type: Article

References (27)

1. Barraud, L and Merle, P and Soma, E and Lefrancois, L and Guerret, S and Chevallier, M and Dubernet, C and Couvreur, P and Trepo, C and Vitvitski, L. (2005) Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo J Hepatol, 42, pp. 629-631.
2. Barth, RF. (1998) Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas J Neurooncol, 36, pp. 91-102.
3. Begley, DJ. (2004) Delivery of therapeutic agents to the central nervous system: The problems and the possibilities Pharmacol Ther, 104, pp. 29-45.
4. Berger, W and Elbling, L and Hauptmann, E and Micksche, M. (1997) Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small lung cancer cells Int J Cancer, 73, pp. 84-93.
5. Bradford, MM. (1976) A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem, 72, pp. 248-254.
6. Couvreur, P and Kante, B and Roland, M and Guiot, P and Bauduin, P and Speiser, P. (1979) Polybutylcyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties J Pharm Pharmacol, 31, pp. 331-332.
7. Gulyaev, AE and Gelperina, SE and Skidan, IN and Antropov, AS and Kivman, GY and Kreuter, J. (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles Pharm Res, 16, pp. 1564-1569.
8. Hu, Y-P and Jarillon, S and Dubernet, C and Couvreur, P and Robert, J. (1996) On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance Cancer Chemother Pharmacol, 37, pp. 556-560.
9. Kreuter, J. (1983) Evaluation of nanoparticles as drug-delivery systems. I: Preparation methods Pharm Acta Helv, 58, pp. 196-209.
10. Kreuter, J. (2002) Transport of drugs across the blood-brain barrier by nanoparticles Curr Med Chem, 2, pp. 241-249.
11. Kreuter, J and Ramge, P and Petrov, V and Hamm, S and Gelperina, SE and Engelhardt, B and Alyautdin, R and von Briesen, H and Begley, DJ. (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm Res, 20, pp. 409-416.
12. Langer, K and Seegmüller, E and Zimmer, A and Kreuter, J. (1994) Characterization of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans Int J Pharm, 110, pp. 21-27.
13. Lee, G and Dallas, S and Hong, M and Bendayan, R. (2001a) Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations Pharmacol Rev, 53, pp. 569-596.
14. Lee, G and Schlichter, L and Bendayan, M and Bendayan, R. (2001b) Functional expression of P-glycoprotein in rat brain microglia J Pharmcol Exp Ther, 299, pp. 204-212.
15. Nerurkar, MM and Burto, PS and Borchardt, RT. (1996) The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system Pharm Res, 13, pp. 528-534.
16. Rieger, J and Roth, W and Glaser, T and Winter, Sn and Rieger, L and Dichgans, J and Weller, M. (1999) Glioblastoma multiforme: Mechanisms of resistance to chemotherapy Neurol Psychiatr Brain Res, 7, pp. 37-46.
17. Rittierodt, M and Harada, K. (2003) Repetitive doxorubicin treatment of globlastoma enhances the P-GP expression - a special role for the endothelial cells Exp Toxic Pathol, 55, pp. 39-44.
18. Ross, KL and Tökés, ZA.(1988) Targeting of drug action to the cell surface by microspheres. In Micospheres: Medical and Biological Applications. (pp. 123-138). Boca Raton, USA: CRC Press.
19. Schlachetzki, F and Pardridge, WM. (2003) P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain Neuroreport, 14, pp. 2041-2046.
20. Sheper, RJ and Bulte, JW and Brakkee, JG and Quak, JJ and van der Schoot, E and Balm, AJ and Meijer, CJ and Broxterman, HJ and Kuiper, CM and Lankelma, J. (1988) Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance Int J Cancer, 42, pp. 389-394.
21. Soma, CE and Dubernet, C and Bentolila, D and Benita, S and Couvreur, P. (2000) Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles Biomaterials, 21, pp. 1-7.
22. Steiniger, SCJ and Kreuter, J and Khalansky, AS and Skidan, IN and Bobruskin, AI and Smirnova, ZS and Severin, SE and Uhl, R and Kock, M and Geiger, KD and Gelperina, SE. (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int J Cancer, 109, pp. 759-767.
23. Walter, KA and Tamargo, RJ and Olivi, A and Burger, PC and Brem, H. (1995) Intratumoral chemotherapy Neurosurgery, 37, pp. 1128-1145.
24. Weyermann, J and Lochmann, D and Zimmer, A. (2005) A practical note on the use of cytotoxicity assays Int J Pharm, 288, pp. 369-376.
25. Woodcock, DM and Linsenmeyer, ME and Chrojnowski, G and Kriegler, AB and Nink, V and Webster, LK and Sawyer, WH. (1992) Reversal of multidrug resistance by surfactants Br J Cancer, 66, pp. 62-68.
26. Yamashima, T and Ohnishi, T and Nakajima, Y and Terasaki, T and Tanaka, M and Yamashita, J and Sasaki, T and Tsuji, A. (1993) Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma Exp Brain Res, 95, pp. 41-50.
27. von Holst, H and Knochenhauer, E and Blomgren, H and Collins, VP and Ehn, L and Lindquist, M and Noren, G and Peterson, C. (1990) Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas Acta Neurochir (Wien), 104, pp. 13-16.